Xeljanz Blood Clots and Deaths: Black-Box Warning Issued
In July 2019, the U.S. Food and Drug Administration approved a black-box warning for the Xeljanz (tofacitinib) drug label due to a higher risk of blood clots and death. The changes followed a review of data from a clinical trial on the safety of Xeljanz and Xeljanz XR in patients with rheumatoid arthritis taking a higher daily dose … [Read more...] about Xeljanz Blood Clots and Deaths: Black-Box Warning Issued
Reports of Xeljanz and Xeljanz XR Blood Clot and Death Risks
FDA Approves New Black Box Warning for Xeljanz and Xeljanz XR Communicating Risk of Blood Clots and Death Xeljanz and Xeljanz XR are Janus Kinase Inhibitors (JAKs) and are part of the class of drugs called “disease-modifying antirheumatic drugs (DMARDs).” Xeljanz and Xeljanz XR are used to treat a variety of medical conditions, … [Read more...] about Reports of Xeljanz and Xeljanz XR Blood Clot and Death Risks
FDA Tofacitinib Warning Released Following Clinical Safety Study
On Friday, the U.S. Food and Drug Administration (FDA) released a drug information update and a drug safety communication concerning recent dangers found in the drug Xeljanz, known generically as tofacitinib. The FDA tofacitinib warning discussed new dangers and how healthcare providers and consumers can safeguard against … [Read more...] about FDA Tofacitinib Warning Released Following Clinical Safety Study
